Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

BMO Capital Maintains Outperform on Y-mAbs Therapeutics, Raises Price Target to $26

Author: Benzinga Newsdesk | March 04, 2024 09:44am

BMO Capital analyst Etzer Darout maintains Y-mAbs Therapeutics (NASDAQ:YMAB) with a Outperform and raises the price target from $16 to $26.

Posted In: YMAB